This is the conventional view. Excluding them is meant to protect pregnant people and their fetuses from unknown risks.
That's 71% of women aged 18-85.
On average, 3-5 different drugs during pregnancy.
But only
Out of 44,160 trials from 2008-2023, only 362 enrolled pregnant people.
Bilinski & Emanuel, AJOG 2025
Among drugs approved since 1980, the vast majority lack adequate evidence.
CDC
Three case studies show how exclusion leads to preventable harm—whether a drug is dangerous or beneficial.
Case Study: Thalidomide (1956-1962)
A sedative prescribed for morning sickness caused severe limb defects. No trial was conducted in pregnant women.
A trial with just 200 participants would have detected the problem before widespread use.
Bilinski, Emanuel & Ciaranello, Annals of Internal Medicine 2025
Case Study: COVID-19 Vaccines (2020-2021)
Despite objections from researchers, initial COVID-19 vaccine RCTs did not include pregnant participants.
8 months after vaccines were authorized. Uptake lagged during the deadly Delta wave.
March–November 2021. That's 71 maternal deaths and 139 stillbirths.
Bilinski, Emanuel & Ciaranello, Annals of Internal Medicine 2025
Case Study: Dolutegravir (2018-2019)
Observational data suggested a safety risk. WHO cautioned against use in women of childbearing age. Later studies proved concerns unfounded.
An RCT would have resolved the safety question faster, preventing the uptake gap that cost lives.
Bilinski, Emanuel & Ciaranello, Annals of Internal Medicine 2025
Excluding pregnant people from trials doesn't protect them—it just prevents researchers from learning when they take medications anyway.
Across all three case studies, trial costs were dwarfed by health benefits.
Three policy levers could close the evidence gap
Read the research:
Research by Dr. Alyssa Bilinski (Brown University), Dr. Natalia Emanuel (Federal Reserve Bank of NY), and Dr. Andrea Ciaranello (MGH/Harvard)